Physician profile
Lima Lawrence
NPI 1154741874
$7,719.72
in general payments reported to CMS, 2019-2025
59 companies · $962 in 2025
The $962 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $626 · 2021: $1,309 · 2022: $1,289 · 2023: $1,705 · 2024: $1,326 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,993.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $700.33 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $600.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $466.53 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.25 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $379.41 | 2019-2025 | Korlym |
| Medtronic, INC. | $364.18 | 2021-2025 | Minimed 780g |
| Amgen INC. | $339.46 | 2019-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $319.93 | 2019-2024 | |
| Abbvie INC. | $277.92 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $243.52 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Antares Pharma, INC. | $198.83 | 2020-2025 | Xyosted |
| Amneal Pharmaceuticals LLC | $193.66 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $193.54 | 2021-2025 | |
| Dexcom, INC. | $186.96 | 2019-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $183.39 | 2020-2025 | Tymlos |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $165.01 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $142.56 | 2019-2022 | |
| Esperion Therapeutics, INC. | $134.70 | 2022-2024 | Nexletol |
| Lifescan, INC. | $117.87 | 2020-2023 | |
| Alvogen INC | $107.96 | 2022-2024 | Teriparatide |
| Amarin Pharma, INC. | $102.57 | 2021-2023 | |
| Becton, Dickinson and Company | $97.30 | 2021-2022 | |
| Astellas Pharma US INC | $95.93 | 2024-2025 | Veozah |
| Horizon Therapeutics Plc | $90.64 | 2021-2023 | Tepezza |
| Pfizer INC. | $88.97 | 2019-2024 | |
| Ascendis Pharma Endocrinology INC | $87.50 | 2023-2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $87.20 | 2021-2022 | |
| Insulet Corporation | $86.78 | 2021-2024 | Omnipod |
| Recordati_rare_diseases_inc. | $86.29 | 2020-2025 | Isturisa, Signifor Lar |
| Medtronic Minimed, INC. | $80.80 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $62.88 | 2021-2024 | Strensiq |
| Mannkind Corporation | $56.95 | 2022-2023 | Afrezza |
| Amryt Pharma Holdings LTD | $56.65 | 2022-2023 | Mycapssa |
| Kyowa Kirin, INC. | $55.50 | 2023-2025 | Crysvita |
| Ibsa Pharma INC. | $54.19 | 2019-2025 | Tirosint, Flector, Licart |
| Beta Bionics, INC. | $48.39 | 2023-2024 | Ilet Bionic Pancreas |
| Verity Pharmaceuticals INC. | $48.27 | 2025 | Tlando |
| Ascensia Diabetes Care US INC. | $46.68 | 2024-2025 | |
| Embecta Corp. | $46.62 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Clarus Therapeutics INC. | $45.86 | 2021 | |
| Sequel Med Tech, LLC | $43.46 | 2025 | Twiist |
| Zealand Pharma US, INC. | $39.70 | 2021-2022 | |
| Nevro Corp. | $35.74 | 2022 | |
| Evoke Pharma, INC. | $35.62 | 2022-2024 | |
| Acella Pharmaceuticals, LLC | $33.32 | 2024-2025 | NP Thyroid 60 |
| Tolmar, INC. | $32.70 | 2023-2025 | Jatenzo |
| Cequr Corporation | $31.32 | 2022-2023 | Cequr Simplicity |
| Averitas Pharma INC. | $31.15 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $28.52 | 2021-2022 | |
| Companion Medical, INC. | $27.94 | 2020 | |
| Neurocrine Biosciences, INC. | $24.07 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $23.72 | 2025 | |
| Tandem Diabetes Care, INC. | $23.39 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $22.91 | 2025 | Rezdiffra |
| Eusa Pharma (US) LLC | $21.06 | 2022 | |
| Vistapharm, INC. | $20.92 | 2021 | |
| Acerus Pharmaceuticals Corporation | $20.65 | 2021 | |
| Shire North American Group INC | $14.30 | 2019 | |
| Valeritas, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lima Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.